GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (MEX:ATAI) » Definitions » EBITDA Margin %

ATAI Life Sciences NV (MEX:ATAI) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ATAI Life Sciences NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ATAI Life Sciences NV's EBITDA for the three months ended in Mar. 2024 was MXN-413.43 Mil. ATAI Life Sciences NV's Revenue for the three months ended in Mar. 2024 was MXN0.00 Mil. Therefore, ATAI Life Sciences NV's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


ATAI Life Sciences NV EBITDA Margin % Historical Data

The historical data trend for ATAI Life Sciences NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV EBITDA Margin % Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - -590.29 -57,544.31 -11,563.83

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87,744.23 -17,975.82 51,287.46 -97,230.39 -

Competitive Comparison of ATAI Life Sciences NV's EBITDA Margin %

For the Biotechnology subindustry, ATAI Life Sciences NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's EBITDA Margin % falls into.



ATAI Life Sciences NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ATAI Life Sciences NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-616.352/5.33
=-11,563.83 %

ATAI Life Sciences NV's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-413.429/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV  (MEX:ATAI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ATAI Life Sciences NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (MEX:ATAI) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.